We are live on ! Find out more
SMV

Sofinnova Management VIII Portfolio holdings

AUM $183M
1-Year Est. Return 4.18%
This Fund
S&P 500
This Quarter Est. Return
-17.21%
1 Year Est. Return
+4.18%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$183M
AUM Growth
+$19.2M
Cap. Flow
+$60.2M
Cap. Flow %
32.85%
Top 10 Hldgs %
100%
Holding
8
New
Increased
2
Reduced
Closed

Top Buys

Rank Stock Value
1
NCNA
NuCana
NCNA
+$50M
2
OBSV
ObsEva SA Ordinary Shares
OBSV
+$10.2M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
NCNA
1
NuCana
NCNA
$6.41M
$47.2M 25.76%
933
+800
+602% +$50M
OBSV
2
DELISTED
ObsEva SA Ordinary Shares
OBSV
$46.4M 25.31%
4,749,623
+1,000,000
+27% +$10.2M
ACRS icon
3
Aclaris Therapeutics
ACRS
$841M
$38M 20.72%
1,539,480
ONCE
4
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$24.7M 13.51%
481,270
NTRA icon
5
Natera
NTRA
$44.6B
$13.9M 7.61%
1,550,280
CYTO
6
DELISTED
Altamira Therapeutics Ltd
CYTO
$4.62M 2.52%
98
OCGN icon
7
Ocugen
OCGN
$451M
$4.26M 2.32%
34,617
SYBX
8
DELISTED
Synlogic
SYBX
$4.12M 2.25%
28,331

Similar funds

Sofinnova Management VIII's Q4 2017 Portfolio in Review

As of Q4 2017, Sofinnova Management VIII held 8 positions worth $183M, up 12% from $164M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Sofinnova Management VIII deployed $60.2M of net new capital in Q4 2017, adding to 2 existing holdings.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Sofinnova Management VIII added most to NuCana in Q4 2017, an estimated $50M increase.
  • Sofinnova Management VIII's ten largest holdings make up 100% of its $183M portfolio in Q4 2017.
  • Sofinnova Management VIII opened 0 new positions and closed 0 in Q4 2017.
  • Sofinnova Management VIII's portfolio value rose 12% quarter-over-quarter to $183M.

Based on Sofinnova Management VIII's 13F filing for Q4 2017, filed 14 Feb 2018.